Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

Dongiovanni, Paola, Petta, Salvatore, Maglio, Cristina, Fracanzani, Anna Ludovica, Pipitone, Rosaria, Mozzi, Enrico, Motta, Benedetta Maria, Kaminska, Dorota, Rametta, Raffaela, Grimaudo, Stefania, Pelusi, Serena, Montalcini, Tiziana, Alisi, Anna, Maggioni, Marco, Kärjä, Vesa, Borén, Jan, Käkelä, Pirjo, Di Marco, Vito, Xing, Chao, Nobili, Valerio, Dallapiccola, Bruno, Craxi, Antonio, Pihlajamäki, Jussi, Fargion, Silvia, Sjöström, Lars, Carlsson, Lena M., Romeo, Stefano, Valenti, Luca·2015·Hepatology
DOI 10.1002/hep.27490

Cited by (532)

Items 401–500 of 532

  1. Újabb adatok a nem alkoholos zsírmáj patogeneziséhez
    Alajos Pár, Gabriella Pár · 2017 · Orvosi Hetilap
  2. Nonalcoholic Fatty Liver Disease
    Carolin Lackner · 2018 · Elsevier eBooks
  3. Nonalcoholic fatty liver disease in lean subjects: is it all metabolic-associated fatty liver disease?
    Mariana Verdelho Machado · 2020 · Hepatoma Research
  4. Nonalcoholic Fatty Liver Disease
    Christopher Paul Day, Quentin Mark Anstee · 2015 · Seminars in Liver Disease
  5. Nonalcoholic Fatty Liver Disease
    Curtis Kent Argo, Zachary H. Henry, Stephen Hugh Caldwell · 2017 · Wiley eBooks
  6. RETRACTED: The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD)
    Lucia Carulli, Giulia Zanca, Filippo Schepis, Erica Villa · 2019 · Metabolites · Retracted
  7. Metabolic-associated fatty liver disease from childhood to adulthood: State of art and future directions
    Francesca Lanzaro, Stefano Guarino, Elisabetta D’Addio, Alessandra Salvatori, Josè Alberto D’Anna, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa · 2022 · World Journal of Hepatology
  8. No association of NAFLD-related polymorphisms in PNPLA3 and TM6SF2 with all-cause and cardiovascular mortality in an Austrian population study
    Georg Semmler, Lorenz Balcar, Sarah Wernly, Leonora Datz, Marie Semmler, Lea Rosenstatter, Felix Stickel, Elmar Stephan Aigner, Bernhard Wernly, Christian Datz · 2023 · Wiener klinische Wochenschrift
  9. Effects of TM6SF2 rs58542926 polymorphism on hepatocellular lipids and insulin resistance in early type 2 diabetes
    Kálmán Benedikt Bódis, Maria Bombrich, Martin Schön, Birgit Knebel, Oana‐Patricia Zaharia, Gidon Josia Bönhof, Yanislava Karusheva, Klaus Straßburger, Yuliya Kupriyanova, Jörg Kotzka et al. · 2023 · Nutrition Metabolism and Cardiovascular Diseases
  10. The association of adiponectin gene polymorphisms with susceptibility and progression of NAFLD in a cohort of Egyptian patients
    Eman Medhat Hasan, Rasha Ahmed Abd Al Aziz, Dina Sabry, Hedy A. Badary, Yasmine Gaber, Ayman Yosry, Zeinab Zakaria · 2021 · Egyptian Liver Journal
  11. Hígado graso (parte 1): aspectos generales, epidemiología, fisiopatología e historia natural
    Jhon Edison Prieto Ortíz, Carlos Bernardo Sánchez Luque, Rolando José Ortega Quiróz · 2022 · Revista Colombiana de Gastroenterología
  12. Update on cardiovascular risk in nonalcoholic fatty liver disease
    Michael Patrick Johnston, Janisha Patel, Christopher D. Byrne · 2021 · Current Opinion in Cardiology
  13. Non-alcoholic Fatty Liver Disease: A Global Public Health Issue
    Eda Kaya, Yusuf Nadir Yilmaz · 2020 · Springer eBooks
  14. Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC)
    Davide Misceo, Gabriele Mocciaro, Simona D’Amore, Michèle Vacca · 2024 · Nutrition & Metabolism
  15. Are we ready for genetic testing in metabolic dysfunction‐associated steatotic liver disease?
    Adele Tulone, Grazia Pennisi, Carlo Ciccioli, Giuseppe Infantino, Claudia La Mantia, Roberto Cannella, Francesco Mercurio, Salvatore Petta · 2024 · United European Gastroenterology Journal
  16. Diagnosis and Management of Fatty Liver
    Phei Oon Tan, Nazri Mustaffa, Soek Siam Tan, Yeong Yeh Lee · 2020 · The Journal of the Royal College of Physicians of Edinburgh
  17. Old-fashioned and newly discovered biomarkers: the future of NAFLD-related HCC screening and monitoring
    Roberto Piciotti, Miriam Longo, Adele Agresta, Erika Paolini, Annalisa Cespiati, Marica Meroni, Paola Dongiovanni · 2022 · Hepatoma Research
  18. Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease
    Marica Meroni, Miriam Longo, Paola Dongiovanni · 2020 · Exploration of Medicine
  19. Sterol Ferulate Rich Wheat Bran Oil Concentrate Prevents Liver Damage in MAFLD Mouse Model by Modulating FAS and PCSK9
    Sharanappa T. Talawar, Kiran Gangappa, Sharavana Gurunathan, V. P. Mayookha, Suresh Kumar Gurusiddaiah · 2021 · ACS Food Science & Technology
  20. On Stress and the Liver: A Chicken and Egg Conundrum
    Herbert L. Bonkovsky · 2015 · Gastroenterology
  21. Cause-specific mortality in lean individuals with metabolic dysfunction-associated steatotic liver disease
    Ziqi Zhang, Jiying Lu, Milian Chen, Liang Dai, Yingying Xiang, Zhidong Liu, Ying Cao, Wei Sheng, Chunlin Li, Deji Song et al. · 2025 · Lipids in Health and Disease
  22. MASLD and the cardiovascular-kidney-liver-metabolic syndrome
    Angeliki M. Angelidi, Chrysoula Boutari, Michail Kokkorakis, Konstantinos Stefanakis, Dimitri P. Mikhailidis, George Jacob, Christos Socrates Mantzoros · 2026 · Endocrine Reviews
  23. Influence of nonalcoholic fatty liver disease severity on carotid adventitial vasa vasorum
    José León, Enric Sánchez, F Herrerias, Mari Cruz de la Fuente, Maite Santamaría, José Manuel Valdivielso, Marcelino Bermúdez-López, Eva Castro, Judit Pallarés, Xavier Matías‐Guiu et al. · 2024 · Frontiers in Endocrinology
  24. TM6SF2 reduces lipid accumulation in vascular smooth muscle cells by inhibiting LOX-1 and CD36 expression
    Tingting Li, Yuting Cui, Tao‐Hua Li, Qiong Xiang, Yanyu Chen, Xi‐Long Zheng, Juan Peng, Zhi‐Han Tang · 2023 · Experimental Cell Research
  25. Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study
    Mario Masarone, Benedetta Maria Motta, Pietro Torre, Marco Aquino, Federica Belladonna, Martina Lombardi, Jacopo Troisi, Marcello Persico · 2024 · Internal and Emergency Medicine
  26. Intestinal TM6SF2 and the gut-liver axis in MASLD: new insights
    Markos Kalligeros, Linda L Henry, Zobair M. Younossi · 2025 · Metabolism and Target Organ Damage
  27. A fatty liver leads to a broken heart?
    Leon Anton Adams, Quentin Mark Anstee · 2016 · Journal of Hepatology
  28. NAFLD and Insulin Resistance: A Multisystemic Disease
    Amalia Gastaldelli · 2020 · Springer eBooks
  29. Comparative efficacy and safety of traditional Chinese patent medicine for NAFLD in childhood or adolescence
    Yuli Sun, Zhaofeng Tan, Zhenyuan Jiang, Min Li, Weiqin Wang, Yaoyao Huang, Jianguang Sun · 2021 · Medicine
  30. Genetic and Hormonal Control of Hepatic Steatosis in Female and Male Mice
    Frode Norheim, S. Hui, Jake Lusis · 2016 · Journal of Hepatology
  31. Relationship between AGT rs2493132 polymorphism and the risk of coronary artery disease in patients with NAFLD in the Chinese Han population
    Mengzhen Dong, Shousheng Liu, Mengke Wang, Yifen Wang, Yongning Xin, Shiying Xuan · 2021 · Journal of International Medical Research
  32. Hepatic microRNA modulation might be an early event to non-alcoholic fatty liver disease development driven by high-fat diet in male mice
    Carolina Panzarin, Laís Angélica de Paula Simino, Mariana Camargo Silva Mancini, Letícia Martins Ignácio-Souza, Marciane Milanski, Márcio Alberto Torsoni, Adriana Souza Torsoni · 2022 · Molecular Biology Reports
  33. Epicardial fat in patients with non-alcoholic fatty liver disease
    Salvatore Petta, Antonio Craxı̀ · 2015 · Journal of Hepatology
  34. Non-alcoholic fatty liver disease and cardiovascular disease: A still debated liaison
    Paola Dongiovanni, Massimiliano Ruscica · 2019 · European Journal of Preventive Cardiology
  35. Antioxidant Role of Kaempferol in the Management of Hepatocellular Carcinoma
    Nidhi Sharma, Subhrajit Biswas, Noura Al‐Dayan, Maryam Sarwat · 2021 · Preprints.org
  36. Impact of fibrosis on liver‐related event incidence in nonalcoholic fatty liver disease: A multicenter observational study
    Kazuaki Chayama, Akira Hiramatsu, Toshihide Shima, Yoshito Itoh, Kanji Yamaguchi, Tomoaki Nakajima, Kyoko Tomita Hoshikawa, Yusuke Kawamura, Norio Akuta, Kiyoaki Ito et al. · 2023 · Hepatology Research
  37. Managing HCC in NAFLD
    Darren Hiu-Sun Foog, D. Kwok, B. Yu, V. Wong · 2017 · Current Hepatology Reports
  38. Non-Alcoholic Fatty Liver Disease as a Coronary Heart Disease Severity Predictor
    Hossam Ismael, Mohammed Tag‐Adeen, Ahmed M. Abdelrady, Mohamed El‐Shazly, Ahmed Ali Hussein · 2020 · International Journal of Clinical Medicine
  39. Steatotic Shadows: The Dark Link Between Metabolic Dysfunction-associated Steatotic Liver Disease and Cancer Risk
    Shakta Mani Satyam, Mohamed El‐Tanani, Syed Arman Rabbani, Alaa A. A. Aljabali, Yahia El‐Tanani, Dimitrios Patoulias, Manfredi Rizzo · 2025 · Current Pharmaceutical Design
  40. From “two hit theory” to “multiple hit theory”: Implications of evolution of pathogenesis concepts for treatment of non-alcoholic fatty liver disease
    Qin Liu, Chun-Yan Niu · 2019 · World Chinese Journal of Digestology
  41. Abnormal Liver Blood Tests: Hepatologist Approach
    Miodrag N Krstic, Dragana Danilo Mijac, Ratko Tomašević, Snežana Lukić, Milica Stojković Lalošević, Jovan M. Krstić, Tomica Milosavljević · 2021 · Digestive Diseases
  42. Hypertension and hepatic triglycerides content
    Gianluca Perseghin, Giuseppina Manzoni, Guido M. Grassi · 2017 · Journal of Hypertension
  43. MARC1 and HNRNPUL1: Two Novel Players in Alcohol-related Liver Disease
    Stefano Romeo · 2020 · Gastroenterology
  44. TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
    Andrea Marco Caddeo, Rosellina Margherita Mancina · 2024 · Clinical and Molecular Hepatology
  45. Are transmembrane 6 superfamily member 2 gene polymorphisms associated with steatohepatitis after pancreaticoduodenectomy?
    Tomotaka Mori, Eisuke Ozawa, Ryu Sasaki, Akane Shimakura, Kosuke Takahashi, Yoko Kido, Yasuko Kanda, Satoshi Matsuo, Kazuaki Tajima, Asami Beppu et al. · 2024 · JGH Open
  46. Identification of biomarkers between coronary artery disease and non-alcoholic steatohepatitis: a combination of bioinformatics and machine learning
    Yi‐Hung Lin, Jingmei Song, Xiaohong Li · 2025 · Frontiers in Genetics
  47. Association of estimated liver fibrosis with carotid but not femoral atherosclerotic burden: the ILERVAS cohort
    Josep Leon Mengibar, Marı́a M. Malagón, Marcelino Bermúdez-López, José Manuel Valdivielso, Reinald Pamplona, G.F. Torres, Dı́dac Mauricio, Eva Castro, Elvira Fernández, Assumpta Caixàs et al. · 2026 · Frontiers in Endocrinology
  48. Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment
    Julia Kozlitina, Stefano Romeo, Helen H. Hobbs · 2026 · Hepatology
  49. Is MASLD an independent risk factor for micro- and macrovascular complications of diabetes? A critical reappraisal and future directions
    SABINE KAHL, Cyrielle Caussy, Kenneth J. Cusi · 2026 · Diabetologia
  50. Molecular mechanisms and pathogenesis of MASH
    Suchira Gallage, Olivier Govaere, Quentin Mark Anstee, Gerald I. Shulman, Frank Tacke, Mathias F Heikenwälder · 2026 · Nature
  51. Genetic and Epigenetic Associations of NAFLD: Focus on Clinical Decision Making
    Mayada Metwally, Mohammed Eslam, Jacob George · 2017 · Current Hepatology Reports
  52. Cardiovascular disease in metabolic-associated fatty liver disease
    Leon Anton Adams · 2023 · Current Opinion in Endocrinology Diabetes and Obesity
  53. Parental History of Type 2 Diabetes Mellitus and PNPLA3 Polymorphism Increase the Risk of Severe Stages of Nonalcoholic Fatty Liver Disease
    Natalia Balassiano Wajsbrot, Nathalie Carvalho Leite, Paulo Henrique Condeixa de França, Claudia R.L. Cardoso, Gil Fernando Salles, Cristiane Alves Villela‐Nogueira · 2023 · Digestive Diseases and Sciences
  54. Frontiers and prospects of pharmacotherapy for non-alcoholic fatty liver disease
    Shanshan Zhang, Laiyou Wang · 2019 · World Chinese Journal of Digestology
  55. The Natural History of NAFLD: Environmental vs. Genetic Risk Factors
    L. Valenti, S. Pelusi · 2020 · Springer eBooks
  56. The rs4686434 variant in the fetuin B (FETUB) locus is associated with intrahepatic triglyceride content in obese Chinese adults
    Zhibin Li, Mingzhu Lin, Changqin Liu, Zheng Chen, Dongmei Wang, Xiulin Shi, Shuyu Yang, Xuejun Li · 2018 · Journal of Diabetes
  57. Rola samorzadu terytorialnego w rozwoju lokalnym
    Jerzy J. Parysek · 1995 · Studia. Polska Akademia Nauk. Komitet Przestrzennego Zagospodarowania Kraju
  58. Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades
    Rosa Lombardi, Lucia Colavolpe, Francesca Alletto, Annalisa Cespiati, Erika Fatta, Cristina Bertelli, Felice Cinque, Giuseppina Pisano, Edoardo Alessandro Pulixi, Paolo Francione et al. · 2023 · Digestive and Liver Disease
  59. Psoriasis and steatotic liver disease: Are PNPLA3 and TM6SF2 polymorphisms suitable for the hepato-dermal axis hypothesis?
    Luciana Agoglia, Ana Carolina Cardoso, Lívia Barbosa, Cecília Schubert Xavier Lagalhard Victer, Sueli Coelho da Silva Carneiro, Paulo Henrique Condeixa de França, Maria Chiara Chindamo, Cristiane Alves Villela‐Nogueira · 2024 · Annals of Hepatology
  60. Down-regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development
    M. Meroni, Paola Dongiovanni, Raffaela Rametta, Giulia Alessandra Bassani, Sara Badiali, Silvia Rossana Fargion, Stefano Romeo, Stefano Gatti, Luca V. C. Valenti · 2017 · Journal of Hepatology
  61. Fígado Gordo Não Alcoólico: Revisão da Literatura
    Luís Costa Matos · 2017 · Gazeta Médica
  62. Genetic Confounders of Liver Stiffness and Controlled Attenuation Parameter
    Vanessa Rausch, Johannes H. Mueller, Sebastian Mueller · 2020 · Springer eBooks
  63. Genome‐wide Association Study of Liver‐related Enzymes Suggests Putative Pleiotropic Effects on Diverse Traits and Diseases
    Hyun-seok Kim, Silvia C. Sookoian, Rubén Hernáez · 2021 · Hepatology
  64. Can genetic influence in non‐alcoholic fatty liver disease be ignored?
    Yang‐Lin Liu, Christopher Paul Day, Quentin Mark Anstee · 2016 · Wiley eBooks
  65. Non-Alcoholic Fatty Liver Disease and Steatohepatitis
    Olivier Govaere, Quentin Mark Anstee · 2022 · Elsevier eBooks
  66. The Genetics of Alcohol-Related Liver Disease
    Hamish A. Innes, Felix Stickel · 2023 · Springer eBooks
  67. Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances
    Caesar Ferrari, Bilal Ashraf, Zainab Hassan Saeed, Micheal S. Tadros · 2024 · Gastroenterology Insights
  68. Artificial intelligence as a ploy to delve into the intricate link between genetics and mitochondria in patients with MASLD
    Miriam Longo, Erika Paolini, Marica Meroni, Michela Ripolone, Laura Napoli, Francesco Gentile, Annalisa Cespiati, Elena Trombetta, Rosa Lombardi, Marco Maggioni et al. · 2025 · JHEP Reports
  69. Genetic Modulators of Disease Penetrance
    Yunjun Kang, Theodore G. Drivas · 2026 · Annual Review of Biomedical Data Science
  70. Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy
    Maurizio Averna, M. Mahmood Hussain, Giuseppe Danilo Norata · 2026 · Nature Reviews Cardiology
  71. Combination of L-Carnitine and Angiotensin-II type 1 Receptor Blocker has Beneficial Effects on Hepatic Fibrosis in a Non-Alcoholic Steatohepatitis Rat Model
    Hideto Kawaratani · 2019 · Biomedical Journal of Scientific & Technical Research
  72. An Insight into the Genetic Predisposition of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Africa
    Yusuf Moolla, Veron Ramsuran · 2024 · Liver international communications.
  73. A Novel Phosphoinositide-3-kinase Adapter Protein 1 Gene Missense Mutation in Familial Cirrhosis
    Cyriac Abby Philips, Meenal Agarwal, Nikhil Phadke, Sasidharan Rajesh, Guruprasad Padsalgi, Rizwan Ahamed, Philip Augustine · 2019 · Journal of Clinical and Experimental Hepatology
  74. Using metabolomics to develop precision medicine strategies to treat nonalcoholic steatohepatitis
    Marta Iruarrizaga‐Lejarreta, Enara Arretxe, Cristina Alonso · 2019 · Expert Review of Precision Medicine and Drug Development
  75. Relationship between non-alcoholic fatty liver disease and cardiovascular disease
    Zhao-Chun Chi · 2020 · World Chinese Journal of Digestology
  76. Role of molecular genetic factors in pathogenesis and diagnosis of non-alcoholic fatty liver disease (literature review and own data)
    D. V. Sidorenko, В. Д. Назаров, Sergey Vladimirovich Lapin, Vladimir Leonidovich Emanuel · 2020 · Medical alphabet
  77. Genetisches Risiko bei metabolischer Fettlebererkrankung
    Roman Liebe, Verena Keitel · 2020 · Der Diabetologe
  78. Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Rosa Lombardi, Giuseppina Pisano, Silvia Rossana Fargion, Anna Ludovica Fracanzani · 2021 · Exploration of Medicine
  79. Genetic predictors and pathophysiological features of non-alcoholic fat liver disease
    Olga Valentinovna Smirnova, Olga Leonidovna Moskalenko, Э. В. Каспаров, И. Э. Каспарова · 2021 · Meditsinskiy sovet = Medical Council
  80. Down-regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development
    M. Meroni, P. Dongiovanni, M. Longo, Raffaella Rametta, S. Badiali, S. Fargion, Stefano Romeo, S. Gatti, Luca V. C. Valenti · 2018 · Journal of Hepatology
  81. Nonalcoholic Fatty Liver Disease
    Vi Nguyen, Ariel E. Feldstein · 2021 · Elsevier eBooks
  82. [Medical-historical survey on epilepsy and older concepts about the therapy of epilepsy].
    E Vencovský · 1972 · PubMed
  83. Genomic studies in non-alcoholic fatty liver disease
    Yang‐Lin Liu · 2017
  84. Clinical Genomics of NAFLD
    Frank Lammert · 2020 · Wiley eBooks
  85. Artificial intelligence as a ploy to delve into the intricate relationship between genetics and mitochondria in MASLD patients
    Miriam Longo, Erika Paolini, Marica Meroni, Michela Ripolone, Laura Napoli, Francesco Gentile, Annalisa Cespiati, Marco Maggioni, Anna Alisi, Luca Miele et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  86. Age might confound the impact of the transmembrane 6 superfamily member 2 E167K polymorphism on hepatic fibrosis in hepatitis C virus–infected patients
    Zhengtao Liu, Tianchi Chen, Yan Wang, Min Zhang, Lin Zhou, Shusen Zheng · 2015 · Hepatology
  87. Susceptibility to chronic liver disease
    Maria Antonella Burza · 2015 · Gothenburg University Publications Electronic Archive (Gothenburg University)
  88. Reply
    Stefano Romeo, Alessio Aghemo, Thomas Berg, Felix Stickel, Luca V. C. Valenti · 2015 · Hepatology
  89. Genetic Basis of Alcoholic and Nonalcoholic Fatty Liver Disease
    Silvia C. Sookoian, Carlos Jose Pirola · 2015 · Springer eBooks
  90. Reply
    Silvia C. Sookoian, Carlos Jose Pirola · 2014 · Hepatology
  91. Fettleberdiagnostik bei Diabetes mellitus Typ 2
    Christoph Grander, Herbert Tilg · 2016 · Der Diabetologe
  92. PNPLA3 Variant p.I148M and Bariatric Surgery
    Roman Liebe, Frank Lammert, Marcin Jan Krawczyk · 2016 · Elsevier eBooks
  93. A two gene-based risk score predicts alcoholic cirrhosis development in males with at-risk alcohol consumption
    Flaminia Ferri, Rosellina Margherita Mancina, M. Mischitelli, Alessio Farcomeni, E Poli, Lucia Parlati, Maria Antonella Burza, Adriano De Santis, Claudia Codazzo, Fabio Attilia et al. · 2017 · Journal of Hepatology
  94. Effects of LXRα phosphorylation on the regulation of lipid metabolism and hepatic fibrosis
    Natalia Bécares · 2017 · UCL Discovery (University College London)
  95. In Vitro Drug Metabolism and Population Pharmacokinetics as Tools for Elucidating Pharmacokinetic Variability
    Enoch Cobbina · 2018 · Digital Commons - URI (University of Rhode Island)
  96. Don’t forget to ask how mum and dad are doing
    Stefano Romeo · 2019 · Liver International
  97. Health aberrations in children with overweight and obesity
    Karnebeek · 2020
  98. Genes and NAFLD/NASH Progression
    Rasha El Sharkawy, Jacob George, Mohammed Eslam · 2020 · Springer eBooks
  99. Mechanisms of Fibrogenesis in NASH
    Mirella Pastore, Alessandra Gentilini, Fabio Marra · 2020 · Springer eBooks
  100. Cardiovascular risk factors in patients with NAFLD and its relationship with the gut microbiota
    O. G. Kurinna · 2020 · Ukrainian Therapeutical Journal